Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has, pursuant to previously announced information, conducted a Directed Share Issue. The Directed Share Issue has resulted in a change in the number of shares and votes in the company. Through the Directed Share Issue, the number of shares has increased by 44,408,008 B-shares and the number of votes has increased by 44,408,108.

During December, shareholders exercised 2,245 warrants (TO4B). The number of shares has increased by 2,245 B-shares during the subscription period, and the number of votes has increased by 2,245. The number of warrants remaining for future subscription periods is 1,414,141. The terms of the warrants are published on Episurf Medical’s website.

Upon request by shareholders in Episurf Medical AB, conversions of class A-shares to B-shares were carried out during December in accordance with the Articles of Association. Through the conversions, the number of A-shares has decreased by 100,002, and the number of B-shares has increased by the same amount. Consequently, the total number of shares in the company has not changed through the conversions, but the total number of votes in the company has decreased by 200,004.

As a consequence of the above-mentioned changes, the total number of shares amounts to 266,539,986, of which 851,018 are A-shares, and 265,688,968 are B-shares. The total number of votes after the changes amounts to 268,242,022.

For more  information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on December 30, 2021.